{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:27Z","timestamp":1787027067884,"version":"build-2736575974"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    This case report describes a fatal case of toxic epidermal necrolysis (TEN) in a 67-year-old man with stage IIIB lung adenocarcinoma (T\n                    <jats:sub>4<\/jats:sub>\n                    N\n                    <jats:sub>2<\/jats:sub>\n                    M\n                    <jats:sub>0<\/jats:sub>\n                    ), which developed 7 days after a single dose of pucotenlimab, a novel programmed death-1 (PD-1) inhibitor. The full course of thoracic radiotherapy was completed prior to immunotherapy initiation, and no persistent hypersensitivity reactions were documented despite concomitant antibiotic administration throughout this period. The patient presented with scattered erythematous papules that rapidly progressed to extensive epidermal detachment involving approximately 80% of the total body surface area (BSA). A baseline SCORTEN score of 6 calculated within 24 hours of readmission (\n                    <jats:xref>\n                      <jats:bold>Table\u00a01<\/jats:bold>\n                    <\/jats:xref>\n                    ) indicated a predicted mortality &amp;gt;90%, and the Naranjo Scale yielded a score of 6 (\n                    <jats:xref>\n                      <jats:bold>Table\u00a02<\/jats:bold>\n                    <\/jats:xref>\n                    ), confirming a probable causal association between TEN and pucotenlimab. Acute-phase immunological profiling revealed markedly reduced PD-1 expression on circulating T cells and significantly elevated interleukin-6 (IL-6), providing exploratory evidence for aberrant T-cell activation as a potential pathogenic mechanism. Despite intensive multidisciplinary management with systemic corticosteroids, intravenous immunoglobulin (IVIG) and supportive care, the patient\u2019s condition progressively deteriorated. After written informed consent for withdrawal of life-sustaining treatment was obtained from the patient\u2019s legal next of kin, the patient was discharged on July 31 and succumbed to his illness shortly thereafter. This case highlights the fatal risk of rare severe cutaneous immune-related adverse events (irAEs) associated with PD-1 inhibitors. It also emphasizes the importance of early recognition, prompt discontinuation of further PD-1 inhibitor administration, and timely combination therapy with corticosteroids and etanercept to improve outcomes in high-risk patients.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1790323","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:39:14Z","timestamp":1782448754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Fulminant toxic epidermal necrolysis induced by pucotenlimab in a patient with lung adenocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10787-024-01590-0","article-title":"Cyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments","volume":"33","author":"Nazerian","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013130.pub2","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01787-z","article-title":"Pucotenlimab: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment","volume":"192","author":"Hama","year":"2024","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxac038","article-title":"CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy","volume":"34","author":"Ando","year":"2022","journal-title":"Int Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101301","article-title":"Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study","volume":"4","author":"Zhang","year":"2023","journal-title":"Cell Rep Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1038\/s41467-024-52990-3","article-title":"Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"15","author":"Gibson","year":"2024","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.05.002","article-title":"Updates in the pathogenesis of SJS\/TEN","volume":"74","author":"Justice","year":"2025","journal-title":"Allergol Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.039","article-title":"Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients","volume":"86","author":"Ao","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","article-title":"Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: Diagnosis and management","volume":"25","author":"Shah","year":"2024","journal-title":"Am J Clin Dermatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1790323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:39:18Z","timestamp":1782448758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1790323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1790323"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1790323","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1790323"}}